Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · Real-Time Price · USD
1.710
-0.020 (-1.16%)
Nov 22, 2024, 4:00 PM EST - Market closed

Company Description

Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States.

Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.

The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex.

Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Ikena Oncology, Inc.
Ikena Oncology logo
Country United States
Founded 2016
IPO Date Mar 26, 2021
Industry Biotechnology
Sector Healthcare
Employees 43
CEO Mark Manfredi

Contact Details

Address:
645 Summer Street, Suite 101
Boston, Massachusetts 02210
United States
Phone 857 273 8343
Website ikenaoncology.com

Stock Details

Ticker Symbol IKNA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001835579
CUSIP Number 45175G108
ISIN Number US45175G1085
SIC Code 2836

Key Executives

Name Position
Dr. Mark Manfredi Ph.D. President, Chief Executive Officer and Director
Dr. Jotin Marango M.D., Ph.D. Chief Financial Officer and Head of Corporate Development
Rebecca Cohen Vice President of Investor Relations, Corporate Strategy and Communication
Jeffrey Ecsedy Ph.D. Chief Development Officer
Bob Lally Senior Vice President of Finance and Operations
David Damphousse M.S. Senior Vice President of Clinical Development Operations
Dr. Caroline Germa M.D., Ph.D. Chief Medical Officer
Valdas Jurkauskas Ph.D. Senior Vice President of Technical Operations

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 7, 2024 10-Q Quarterly Report
Aug 8, 2024 10-Q Quarterly Report
Jul 12, 2024 8-K Current Report
Jun 10, 2024 8-K Current Report
May 28, 2024 8-K Current Report
May 13, 2024 10-Q Quarterly Report
Apr 26, 2024 ARS Filing
Apr 26, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material